scholarly journals Clinical trials update of the European Organization for Research and Treatment of Cancer Breast Cancer Group

2004 ◽  
Vol 6 (4) ◽  
Author(s):  
Emiel JT Rutgers ◽  
Philip Meijnen ◽  
Hervé Bonnefoi
Keyword(s):  
Breast Cancer ◽  
Clinical Trials ◽  
European Organization ◽  
Cancer Group ◽  
Cancer Breast ◽  
Breast Cancer Group

scholarly journals European Organization for Research and Treatment of Cancer – Breast Cancer Group (EORTC BCG)

2006 ◽  
Vol 9 (S1) ◽  
pp. 110-130
Author(s):  
Keyword(s):  
Breast Cancer ◽  
Locally Advanced ◽  
Operable Breast Cancer ◽  
Phase Iii ◽  
European Organization ◽  
Node Negative ◽  
Cancer Group ◽  
Cancer Breast ◽  
Breast Cancer Group ◽  
Phase Iii Study

This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by European Organization for Research and Treatment of Cancer – Breast Cancer Group (EORTC BCG). Clinical trials include: Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for node-negative and node-positive patients with operable breast cancer. EORTC Study No. 10901Randomized phase III study comparing short, intensive preoperative combination chemotherapy with similar therapy given postoperatively. EORTC Trial No. 10902Phase III randomized trial investigating the role of internal mammary and medial supraclavicular (IM-MS) lymph node chain irradiation in stage I–III breast cancer (joint study of the EORTC Radiotherapy Cooperative Group and the EORTC Breast Cancer Cooperative Group). EORTC Study No. 10925/22922A survey of the Breast International Group (BIG) to assess the attitude of patients aged <35 years, with early breast cancer, toward the risk of loss of fertility related to adjuvant therapies. BIG 3-98/EORTC 10002LAMANOMA: Conservative local treatment versus mastectomy after induction chemotherapy in locally advanced breast cancer: a randomized phase III study. BIG 2-00/EORTC Study No. 10974/22002p53 study: First prospective intergroup translational research trial assessing the potential predictive value of p53 using a functional assay in yeast in patients with locally advanced/inflammatory or large operable breast cancer, prospectively randomized to a taxane versus non-taxane regimen. BIG 1-00/EORTC 10994After mapping of the axilla: radiotherapy or surgery AMAROS. EORTC 10981/22023A randomized phase II–III trial evaluating the efficacy of capecitabine and vinorelbine in anthracycline and taxane pretreated metastatic breast cancer. EORTC 10001/160010Phase I study of lonafarnib (SCH 66336) in combination with Herceptin plus paclitaxel in HER-2 neu overexpressing breast cancer. EORTC 10051/16023MINDACT trial: A prospective, randomized study comparing the Amsterdam 70-gene expression signature (Mammaprint) with common clinical pathological criteria in selecting patients for adjuvant chemotherapy in node-negative breast cancer. BIG 3-04/EORTC 10041

scholarly journals Finnish Breast Cancer Group (FBCG)

2006 ◽  
Vol 9 (S1) ◽  
pp. 131-137
Author(s):  
Keyword(s):  
Breast Cancer ◽  
Clinical Trials ◽  
Early Breast Cancer ◽  
Single Agent ◽  
Randomised Trial ◽  
Phase Iii ◽  
List Type ◽  
Cancer Group ◽  
Current Contact ◽  
Breast Cancer Group

This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by Finnish Breast Cancer Group (FBCG). Clinical trials include: Comparison of vinorelbine versus docetaxel, and trastuzumab versus no trastuzumab as adjuvant treatments of early breast cancer. FinHer studyRandomized phase III study comparing single-agent docetaxel followed by 5-FU, epirubicin and cyclophosphamide (FEC) to docetaxel plus Xeloda followed by cyclophosphamide, epirubicin and Xeloda (CEX) as adjuvant treatment for early breast cancer. FinXX StudyA multicenter phase III open randomised trial of the efficacy of exercise in the prevention of long-term adverse effects of adjuvant treatments and breast cancer recurrences in women with primary breast cancer. BREX 01-2004 Study

scholarly journals Fondazione Michelangelo Breast Cancer Group (FM-B)

2006 ◽  
Vol 9 (S1) ◽  
pp. 104-109
Author(s):  
Keyword(s):  
Breast Cancer ◽  
Clinical Trials ◽  
Systemic Therapy ◽  
Operable Breast Cancer ◽  
List Type ◽  
Cooperative Study ◽  
Primary Systemic Therapy ◽  
Cancer Group ◽  
Current Contact ◽  
Breast Cancer Group

This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by Fondazione Michelangelo Breast Cancer Group (FM-B). Clinical trials include: European cooperative study of chemotherapy and surgery comparing adjuvant doxorubicin followed by CMF versus adjuvant doxorubicin/paclitaxel followed by CMF versus primary doxorubicin/paclitaxel followed by CMF in women with operable breast cancer and T > 2cm.European Cooperative Study of Primary Systemic Therapy in Women with Operable Breast Cancer and T > 2cm.

scholarly journals Circulating Plasma miRNA-21 as a Superior Biomarker Compared to CA 15-3: Assessment in Healthy Age Matched Subjects and Different Stage of Breast Cancer Patients

2020 ◽  
Vol 12 (2) ◽  
pp. 157-64
Author(s):  
Merlyna Savitri ◽  
Ugroseno Yudho Bintoro ◽  
Made Putra Sedana ◽  
Muhammad Noor Muhammad ◽  
Pradana Zaky Romadhon ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Control Group ◽  
Breast Cancer Patients ◽  
Circulating Mirna ◽  
Cancer Group ◽  
Significant Difference ◽  
Median Level ◽  
Breast Cancer Group ◽  
Low Sensitivity ◽  
Plasma Mirna

BACKGROUND: Carbohydrate antigens 15-3 (CA 15-3) is a conventional tumor marker in breast cancer, with low sensitivity and specificity. MicroRNA (miRNA)-21 showed its stability in circulation and could serve as powerful biomarker. The aim of this study was to evaluate miRNA-21 as breast cancer biomarker compared to CA 15-3 in Indonesian population.METHODS: Circulating plasma miRNA-21 expression was measured using qRT-PCR in 49 patients at various stages of breast cancer and 16 healthy controls. The relative expression value of miRNA-21 was calculated using 2-ΔΔCt. Meanwhile, CA 15-3 was quantified using electrochemiluminescence immunoassay (ECLIA) methods. The results of miRNA-21 and CA 15-3 plasma circulating expression were compared with controls at each stage and between stages of breast cancer.RESULTS: CA 15-3 median level in breast cancer group was 1.60 times higher compared to control group (p=0.019), 21.00 m/mL and 13.05 m/mL, respectively. Median miRNA-21 expression in breast cancer group was elevated 4.92 folds compared to control group (p=0.001), 4.43 and 0.90, respectively. There was no significant difference of CA 15-3 level between controls and all stages of breast cancer group. CA 15-3 cut-off value was 15.05 m/mL (p=0.016) with 59.2% sensitivity and 62.5% specificity. Meanwhile, there was a significant difference of miRNA-21 expression between controls and most stages of breast cancer group. Circulating miRNA-21 expression cut-off value was 2.07 (p=0.000) with 91.8% sensitivity and 87.5% specificity.CONCLUSION: Circulating miRNA-21 expression and CA 15-3 levels were significantly increased in breast cancer group compared to control group. The miRNA-21 expression increased consistently with breast cancer stage progression. miRNA-21 could serve as superior biomarker compared to CA 15-3.KEYWORDS: biomarker, breast cancer, circulating plasma, liquid biopsy, miRNA-21

scholarly journals Qualidade de Vida Relacionada à Saúde de Pacientes com Câncer de Mama: Revisão Integrativa da Literatura

2020 ◽  
Vol 66 (1) ◽  
Author(s):  
Monique Binotto ◽  
Gilberto Schwartsmann
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Cáncer De Mama ◽  
Life Questionnaire ◽  
European Organization ◽  
Quality Of Life Questionnaire ◽  
Cancer Breast ◽  
Eortc Qlq C30 ◽  
Eortc Qlq

Introdução: O câncer de mama pode alterar a qualidade de vida relacionada à saúde das pacientes. Objetivo: Compreender o impacto da quimioterapia para câncer de mama na qualidade de vida relacionada à saúde de pacientes. Método: Trata-se de uma revisão integrativa da literatura, compreendendo artigos publicados entre 2007 e 2019, disponíveis nas bases de dados PubMed, LILACS e SciELO. Analisaram-se 25 artigos na íntegra. Resultados: Os questionários mais frequentemente utilizados nos estudos foram o European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) e o módulo complementar European Organization for Research and Treatment of Cancer Breast Cancer-specific Quality of Life Questionnaire (EORTC QLQ-BR23). Em relação às alterações da qualidade de vida, a saúde global diminui durante a quimioterapia, mas pode melhorar após o término do tratamento. O aumento dos sintomas é relatado em diversos estudos e prejudicou a qualidade de vida relacionada à saúde das pacientes. Entretanto, os sintomas diminuem após o término da quimioterapia, exceto para algumas escalas. As escalas de imagem corporal, função sexual e funcionamento físico pioram ao longo do tratamento. A qualidade de vida mental/psicológica tem oscilações durante o tratamento, assim como a escala sobre as relações sociais. Conclusão: A qualidade de vida relacionada à saúde de mulheres com câncer de mama é afetada negativamente pelo tratamento quimioterápico, expressando maior impacto nas escalas de sintomas.

Sign in / Sign up

Export Citation Format

Share Document